Safety profile of extended-release niacin in the AIM-HIGH trial.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.PloS one · 2022
   Pooled it
2. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.JAMA network open · 2019 · on this map
   Pooled it
3. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.Heart (British Cardiac Society) · 2016 · on this map
   Pooled it
4. Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
   Trial
5. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.Circulation. Genomic and precision medicine · 2018
   Trial
6. A pilot study of the effects of niacin administration on free fatty acid and growth hormone concentrations in children with obesity.Pediatric obesity · 2018 · on this map
   Trial
7. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.The American journal of medicine · 2016
   Trial
8. Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a).Cardiovascular & hematological disorders drug targets · 2026
   Review
9. Niacin-Induced Syncope in a Middle-Aged Male: When an Over-the-Counter Vitamin Goes Wrong.Cureus · 2023
   Article
10. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
11. Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.Journal of atherosclerosis and thrombosis · 2022
    Article
12. Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2021
    Review
13. Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations.Cardiology and therapy · 2020
    Review
14. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment.Current cardiology reports · 2020
    Review
15. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.Drugs · 2018
    Review
16. Current therapies for lowering lipoprotein (a).Journal of lipid research · 2016
    Review
17. Targeting ApoC-III to Reduce Coronary Disease Risk.Current atherosclerosis reports · 2016
    Review
18. Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead.JACC. Basic to translational science · 2016
    Article
19. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.Current atherosclerosis reports · 2016
    Review
20. Vitamin paradox in obesity: Deficiency or excess?World journal of diabetes · 2015
    Review

Corrections and comments

• Commented on by
  Niacin and HDL cholesterol--time to face facts.2014

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as